IGF-1 LR3
Recherche publiée et base de preuves
Long R3 IGF-I (LR3-IGF-I) is a recombinant analogue of human IGF-I with a 13-amino-acid N-terminal extension and arginine in place of glutamate at position 3, developed in Adelaide in the early 1990s. These changes sharply reduced binding to IGF-binding proteins, and in cell and rodent studies the analogue was several-fold more potent than native IGF-I for anabolic and gut-growth effects despite being cleared from plasma more rapidly. In pigs and marmosets it produced stronger and longer-lasting hypoglycaemia than IGF-I, it suppressed growth hormone in pigs and monkeys, and it reduced growth in pigs. Recent animal studies reported no cognitive benefit in an Alzheimer's mouse model and no growth benefit in growth-restricted fetal sheep. No human studies have been published, and anti-doping laboratories have identified research-grade and degraded forms in black-market products.
- Le LR3-IGF-I est une forme modifiée de l'IGF-I humain avec affinité réduite aux protéines de liaison.
- Les études animales ont rapporté des effets métaboliques plus forts que l'IGF-I natif mais des résultats mitigés.
- Aucune étude humaine n'a été publiée et le composé n'est pas approuvé pour usage humain.
15 études · 4 depuis 2023 · plus récente 2026
- Études citées
- 15
- Publiées 2023+
- 4
- Article le plus récent
- 2026
- Dernière révision
- oct. 2026
Thèmes récurrents dans la littérature
- reduced IGF-binding-protein affinity
- greater potency than native IGF-I in animals
- rapid plasma clearance
- hypoglycaemia
- suppression of the endogenous GH/IGF-I axis
- anti-doping detection and black-market quality
15 études publiées.
Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.
- 01Clinique humaine2023
Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry
Bang P, et al. · J Clin Endocrinol Metab · CONTEXT, not LR3: native recombinant human IGF-1 (mecasermin); Eu-IGFD surveillance registry (NCT00903110), 306 children and adolescents, 2008-2021
In children treated with recombinant human IGF-1 for severe primary IGF-1 deficiency, 80 of 304 analysed patients experienced at least one hypoglycaemia adverse event. A prior history of hypoglycaemia and a diagnosis of Laron syndrome predicted hypoglycaemia; serious hypoglycaemia events occurred at 0.01 per patient per treatment year.
Résultat de sécurité signalé. Hypoglycaemia was the principal adverse event of native recombinant IGF-1 in a long-term paediatric registry (context, not LR3).
- 02Animal in vivo2025
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel MG, et al. · J Alzheimers Dis · male 5XFAD Alzheimer's model mice and wild-type controls, intranasal LR3-IGF-1 or vehicle for 7 months (n = 19-27 per group), plus BV-2 microglial cells
Intranasal LR3-IGF-1 improved body composition and remodelled cortical amyloid plaques, reducing filamentous plaques and low-molecular-weight amyloid-beta oligomers, but did not significantly improve cognitive or behavioural outcomes. In vitro, LR3-IGF-1 enhanced amyloid-beta uptake by microglial cells.
- 03Animal in vivo2025
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep
White A, et al. · Am J Physiol Endocrinol Metab · late-gestation growth-restricted fetal sheep, 1-week direct fetal infusion of IGF-1 LR3 (n = 7) or vehicle (n = 7)
IGF-1 LR3 did not increase fetal body weight and did not change insulin, glucose, oxygen or glucose-stimulated insulin secretion compared with vehicle. Circulating amino acids, notably branched-chain amino acids, decreased with treatment.
- 04Animal in vivo2000
IGF-I but not the IGF-I variant long R(3)IGF-I increases serum IGFBP-3 in adolescent monkeys
Wilson ME, et al. · Growth Horm IGF Res · adolescent female rhesus monkeys (n = 4-6 per group), acute subcutaneous injection and continuous subcutaneous infusion of IGF-I or Long R3 IGF-I versus untreated controls
Native IGF-I raised serum IGFBP-3 after both acute and chronic administration, whereas Long R3 IGF-I did not. Serum growth hormone was acutely suppressed by both IGF-I and Long R3 IGF-I. The analogue did not block the IGFBP-3-raising effect of native IGF-I.
- 05Animal in vivo1997
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys
Tomas FM, et al. · J Endocrinol · pigs and marmoset monkeys, acute bolus comparison of IGF-I with IGF-I variants including LR3IGF-I, with serial blood sampling over 4 hours
IGF-I variants with low IGF-binding-protein affinity, including LR3IGF-I, were 2-3-fold more potent than IGF-I at lowering plasma glucose to the nadir. Glucose suppression lasted much longer, with cumulative hypoglycaemia over four hours roughly 4-8-fold greater; LR3IGF-I was the only variant that lowered plasma amino acids more potently than IGF-I in pigs.
Résultat de sécurité signalé. LR3IGF-I and related variants produced more potent and longer-lasting hypoglycaemia than native IGF-I in pigs and marmosets.
- 06Animal in vivo1997
Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs
Dunaiski V, et al. · J Endocrinol · finisher pigs, 4-day infusion of LR3IGF-I or IGF-I, alone or combined with porcine growth hormone
LR3IGF-I infusion decreased average daily gain and food intake and lowered plasma IGFBP-3, endogenous IGF-I and insulin; mean plasma growth hormone fell by 23% and the area under growth hormone peaks by 60%. Co-administered porcine growth hormone did not restore growth or the suppressed hormones.
Résultat de sécurité signalé. LR3IGF-I suppressed endogenous growth hormone, IGF-I, IGFBP-3 and insulin and reduced growth and food intake in pigs.
- 07Animal in vivo1994
Prolonged administration of IGF peptides enhances growth of gastrointestinal tissues in normal rats
Steeb CB, et al. · Am J Physiol · female rats, 14-day osmotic minipump infusion of IGF-I or LR3IGF-I at graded doses
Both peptides produced dose-dependent increases in gastrointestinal tissue weight, and LR3IGF-I at the highest dose increased total gut weight by 43% and small intestinal weight by 47%. Crypt depth, villus height and crypt cell numbers increased, while the balance between proliferative and maturation compartments was maintained.
- 08Animal in vivo1993
Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs
Ballard FJ, et al. · Growth Regul · L6 myoblasts in vitro plus 14-day administration and plasma clearance studies in normal and pregnant rats, IGF-I versus LR3IGF-I
LR3IGF-I had roughly 1000-fold lower affinity than IGF-I for IGFBP-3, IGFBP-4 and rat plasma binding proteins and was 5-10-fold more potent in cultured myoblasts. In rats it was about 6-fold more potent for growth outcomes yet was cleared from plasma much more rapidly than IGF-I, a difference attributed to its poor association with circulating binding proteins.
- 09Animal in vivo1993
Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats
Tomas FM, et al. · J Endocrinol · growing female rats, 14-day subcutaneous infusion of IGF-I, LR3IGF-I or human growth hormone
IGF-I increased body weight gain, nitrogen retention and food conversion efficiency in a dose-dependent manner, and LR3IGF-I was substantially more potent than native IGF-I. Body proportions were generally maintained; muscle protein synthesis and myofibrillar breakdown both rose slightly, so the improvement in nitrogen retention was not explained by calculated muscle protein accretion.
- 10Animal in vivo1992
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
Tomas FM, et al. · Biochem J · 150 g male rats made catabolic with dexamethasone, 7-day infusion of IGF-I, des(1-3)IGF-I or LR3IGF-I
IGF-I partially reversed dexamethasone-induced weight loss and negative nitrogen balance, and des(1-3)IGF-I and LR3IGF-I were approximately 2.5-fold more potent than IGF-I despite LR3IGF-I binding the type 1 IGF receptor 3-fold less well. The authors linked the greater potency to treatment-induced rises in circulating IGFBP-3, which would restrict native IGF-I but not the analogues.
- 11In vitro2021
Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes
Mongongu C, et al. · Drug Test Anal · analytical method validation in spiked human serum, analysis of black-market products, and single intramuscular administration in rats
The validated immunopurification and high-resolution mass spectrometry method detected IGF-I analogues in serum and found abundant lower-quality, oxidised peptide forms in black-market products. After injection in rats, unchanged LongR3-IGF-I disappeared within about 4 hours, while N-terminally truncated metabolites were detected for up to 16 hours; the same metabolites formed in human whole blood in vitro.
Résultat de sécurité signalé. Black-market IGF-I analogue products contained abundant oxidised and lower-quality peptide forms.
- 12In vitro2000
Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I
Laajoki LG, et al. · J Biol Chem · high-resolution NMR solution structure and backbone dynamics of 15N-labelled Long-[Arg3]-IGF-I
The IGF-I domain of Long-[Arg3]-IGF-I was structurally similar to native IGF-I, with the main differences at the N-terminus, where the first three residues were substantially reoriented. The authors linked these changes to its lower affinity for IGF-binding proteins and reported considerable flexibility, even within the alpha-helices.
- 13In vitro1992
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency
Francis GL, et al. · J Mol Endocrinol · recombinant IGF-I fusion analogues expressed in E. coli, tested in L6 rat myoblasts, H35 hepatoma cells and chicken embryo fibroblasts
The study described production of Long IGF-I, Long [Gly3]-IGF-I and Long [Arg3]-IGF-I (LR3), each carrying an N-terminal extension from porcine growth hormone. In cells that secrete IGF-binding proteins, Long [Arg3]-IGF-I was among the most potent analogues for stimulating protein and DNA synthesis, whereas in cells without detectable binding proteins it was less potent than IGF-I, indicating that its potency derived from reduced binding-protein interaction.
- 14Revue2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, et al. · Front Endocrinol (Lausanne) · narrative clinical review of unregulated peptides acting on the GH-IGF-1 axis, including IGF-1 LR3
The review contrasted published pharmacological and clinical evidence with online self-administration practices and grouped peptides by evidence tier, from regulatory-grade trial data down to a complete absence of human studies. Reported adverse effects across the class included endocrine and metabolic disturbance including dysglycaemia, fluid retention, musculoskeletal symptoms and injection-site reactions, with mitogenic concerns described as biologically plausible but unproven.
Résultat de sécurité signalé. Class-level review of adverse effects reported with unregulated GH/IGF-1-axis peptides, including dysglycaemia and endocrine disturbance.
- 15Rapport de cas2010
Detection of His-tagged Long-R³-IGF-I in a black market product.
Kohler M, et al. · Growth Horm IGF Res · single injection vial obtained from the black market, analysed by immunoaffinity purification, high-resolution mass spectrometry and ELISA
The vial contained Long-R3-IGF-I carrying a C-terminal His6-tag, a form normally produced for biochemical research rather than for injection. The authors noted that the effects of His-tagged Long-R3-IGF-I in humans had not been described.
Résultat de sécurité signalé. Black-market product identified as a research-grade His-tagged form of Long-R3-IGF-I with no human characterisation.
Ce que ces preuves n'établissent pas.
No clinical trial, pharmacokinetic study or safety study of LR3-IGF-I in humans has been published, and the compound has never been approved for human use. Animal results are species-dependent (growth stimulated in rats but inhibited in pigs), and recent disease-model studies were negative on their main functional outcomes. Long-term effects of sustained IGF-1 receptor stimulation, including hypoglycaemia, organ overgrowth and theoretical mitogenic risk, have not been characterised for this analogue; human safety data exist only for native IGF-I (mecasermin).
Questions courantes sur la recherche.
- What is IGF-1 LR3?
Long R3 IGF-I (LR3-IGF-I) is a recombinant analogue of human insulin-like growth factor I developed in Adelaide in the early 1990s. It carries a 13-amino-acid extension at the N-terminus and arginine in place of glutamate at position 3. Those changes sharply reduce its binding to the IGF-binding proteins that normally hold most circulating IGF-I in an inactive form.
- How did IGF-1 LR3 compare with native IGF-1 in animal studies?
In rats it was several-fold more potent than native IGF-I for anabolic and gut-growth effects, even though it was cleared from plasma more quickly. In pigs and marmosets it produced stronger and longer-lasting falls in blood glucose than IGF-I, and in pigs and monkeys it suppressed growth hormone. In pigs it reduced growth rather than increasing it, so its effects were species-dependent.
- Has IGF-1 LR3 been studied in humans?
No clinical trial, pharmacokinetic study or safety study of LR3-IGF-I in humans has been published, and it has never been approved for human use. Human safety data exist only for native IGF-I (mecasermin): in a European registry of 304 children treated for severe primary IGF-I deficiency, 80 had at least one episode of hypoglycaemia. Anti-doping laboratories have identified research-grade and degraded forms of the analogue in black-market products.
Disponible dans notre catalogue
À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.